An 18-Week Multi-Center Randomized Double-Blind Placebo-Controlled Parallel-Group Study Of The Efficacy Safety And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Donepezil (Primary)
- Indications Cognition disorders; Vascular dementia
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 22 Feb 2008 Results were presented at the 2008 American Stroke Association's International Stroke Conference.
- 04 Oct 2007 Status change from in progress to completed.
- 22 Oct 2005 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History